Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3201) 3201
Publication (495) 495
Book Review (89) 89
Conference Proceeding (42) 42
Book Chapter (29) 29
Book / eBook (19) 19
Dissertation (6) 6
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2275) 2275
index medicus (1991) 1991
respiratory system (1807) 1807
male (1388) 1388
female (1306) 1306
idiopathic pulmonary fibrosis (1258) 1258
pulmonary fibrosis (1123) 1123
idiopathic pulmonary-fibrosis (1094) 1094
middle aged (1030) 1030
aged (947) 947
mortality (884) 884
lung diseases (713) 713
respiratory tract diseases (635) 635
prognosis (628) 628
diagnosis (580) 580
survival (570) 570
fibrosis (511) 511
pneumonia (480) 480
adult (465) 465
retrospective studies (458) 458
interstitial lung disease (449) 449
research (436) 436
risk factors (428) 428
animals (419) 419
care and treatment (405) 405
disease (398) 398
abridged index medicus (378) 378
critical care medicine (378) 378
idiopathic pulmonary fibrosis - mortality (372) 372
treatment outcome (323) 323
lung - pathology (316) 316
disease progression (314) 314
biopsy (296) 296
patients (293) 293
analysis (288) 288
idiopathic pulmonary fibrosis - physiopathology (287) 287
idiopathic pulmonary fibrosis - diagnosis (284) 284
aged, 80 and over (277) 277
health aspects (276) 276
pirfenidone (273) 273
lungs (268) 268
idiopathic pulmonary fibrosis - drug therapy (265) 265
pathogenesis (263) 263
medicine (257) 257
acute exacerbation (255) 255
studies (252) 252
mice (241) 241
cardiac & cardiovascular systems (236) 236
tomography, x-ray computed (235) 235
idiopathic pulmonary fibrosis - pathology (225) 225
development and progression (224) 224
medical prognosis (218) 218
inflammation (217) 217
interstitial pneumonia (215) 215
medicine, general & internal (214) 214
prevalence (210) 210
research article (206) 206
survival analysis (204) 204
lung transplantation (200) 200
survival rate (196) 196
fibroblasts (187) 187
respiratory function tests (185) 185
severity of illness index (185) 185
expression (184) 184
medical research (183) 183
alveolitis (182) 182
article (182) 182
lung diseases, interstitial - diagnosis (182) 182
usual interstitial pneumonia (180) 180
review (178) 178
proteins (176) 176
diseases of the respiratory system (169) 169
lung cancer (169) 169
lung (168) 168
lung diseases, interstitial - mortality (168) 168
therapy (167) 167
usage (165) 165
idiopathic pulmonary fibrosis - therapy (163) 163
cancer (160) 160
pulmonary/respiratory (159) 159
surgery (159) 159
cell biology (157) 157
classification (156) 156
hypertension (156) 156
bacterial pneumonia (155) 155
medicine, research & experimental (155) 155
pulmonary and respiratory medicine (154) 154
rheumatology (154) 154
time factors (154) 154
clinical trials (153) 153
follow-up studies (153) 153
interstitial lung-disease (152) 152
patient outcomes (150) 150
medicine, experimental (148) 148
bleomycin (147) 147
transplantation (147) 147
lung - physiopathology (146) 146
management (145) 145
quality of life (145) 145
idiopathic pulmonary fibrosis - genetics (140) 140
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3173) 3173
German (16) 16
French (14) 14
Korean (13) 13
Spanish (12) 12
Chinese (6) 6
Portuguese (6) 6
Japanese (5) 5
Dutch (3) 3
Turkish (2) 2
Czech (1) 1
Danish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
by Olson, Amy L and Swigris, Jeffrey J and Lezotte, Dennis C and Norris, Jill M and Wilson, Carla G and Brown, Kevin K
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 08/2007, Volume 176, Issue 3, pp. 277 - 284
Rationale: From the late 1970s to the early 1990s, studies found that mortality rates for pulmonary fibrosis were increasing. Recent data for mortality from... 
Epidemiology | Mortality rates | Idiopathic pulmonary fibrosis | epidemiology | idiopathic pulmonary fibrosis | RESPIRATORY SYSTEM | mortality rates | CRITICAL CARE MEDICINE | Pulmonary Fibrosis - mortality | United States - epidemiology | Age Factors | Humans | Middle Aged | Sex Factors | Aged, 80 and over | Female | Male | Aged | Mortality - trends | Retrospective Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
by Richards, Thomas J and Kaminski, Naftali and Baribaud, Fred and Flavin, Susan and Brodmerkel, Carrie and Horowitz, Daniel and Li, Katherine and Choi, Jiin and Vuga, Louis J and Lindell, Kathleen O and Klesen, Melinda and Zhang, Yingze and Gibson, Kevin F
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 01/2012, Volume 185, Issue 1, pp. 67 - 76
Rationale: Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology with a variable and unpredictable course. Objectives: The aim of... 
Biomarkers | Adhesion molecules | MMP-7 | Personalized medicine | Mortality prediction | ACTIVATION | INTERCELLULAR-ADHESION MOLECULE-1 | ICAM-1 EXPRESSION | biomarkers | N-ACETYLCYSTEINE | SERUM | CLINICAL-COURSE | personalized medicine | EPITHELIAL-CELLS | GENE | adhesion molecules | RESPIRATORY SYSTEM | MATRILYSIN | mortality prediction | MICE | CRITICAL CARE MEDICINE | Cell Adhesion Molecules - blood | Enzyme-Linked Immunosorbent Assay - methods | Predictive Value of Tests | Matrix Metalloproteinase 7 - blood | Humans | Proportional Hazards Models | Male | Biomarkers - blood | Idiopathic Pulmonary Fibrosis - blood | S100A12 Protein | Vascular Cell Adhesion Molecule-1 - blood | Matrix Metalloproteinase 1 - blood | Idiopathic Pulmonary Fibrosis - mortality | S100 Proteins - blood | Survival Analysis | Female | Intercellular Adhesion Molecule-1 - blood | Aged | Interleukin-8 - blood | Matrix Metalloproteinases - blood | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review
by Hutchinson, John and Fogarty, Andrew and Hubbard, Richard and McKeever, Tricia
European Respiratory Journal, ISSN 0903-1936, 09/2015, Volume 46, Issue 3, pp. 795 - 806
As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. This... 
UNITED-STATES | SURVIVAL | INTERSTITIAL LUNG-DISEASES | ALVEOLITIS | RESPIRATORY SYSTEM | PREVALENCE | EPIDEMIOLOGY | Severity of Illness Index | Global Health | Humans | Middle Aged | Europe - epidemiology | Male | Cause of Death | Incidence | Idiopathic Pulmonary Fibrosis - epidemiology | South America - epidemiology | Idiopathic Pulmonary Fibrosis - diagnosis | Survival Analysis | Adult | Female | Aged | North America - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
by King, Talmadge E and Bradford, Williamson Z and Castro-Bernardini, Socorro and Fagan, Elizabeth A and Glaspole, Ian and Glassberg, Marilyn K and Gorina, Eduard and Hopkins, Peter M and Kardatzke, David and Lancaster, Lisa and Lederer, David J and Nathan, Steven D and Pereira, Carlos A and Sahn, Steven A and Sussman, Robert and Swigris, Jeffrey J and Noble, Paul W and ASCEND Study Grp and ASCEND Study Group
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2083 - 2092
In this randomized, controlled trial, the use of pirfenidone in patients with idiopathic pulmonary fibrosis led to a slower rate of loss in forced vital... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | DISTANCE | PREDICTOR | ALVEOLITIS | INTERSTITIAL PNEUMONIA | CLINICALLY IMPORTANT DIFFERENCE | HISTOLOGIC PATTERN | FORCED VITAL CAPACITY | Enzyme Inhibitors - adverse effects | Antifibrinolytic Agents - therapeutic use | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Male | Treatment Outcome | Antifibrinolytic Agents - adverse effects | Disease Progression | Enzyme Inhibitors - administration & dosage | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Aged, 80 and over | Adult | Female | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Pyridones - therapeutic use | Idiopathic Pulmonary Fibrosis - drug therapy | Pyridones - adverse effects | Pulmonary fibrosis | Analysis | Anti-arrhythmia drugs | Clinical trials | Pharmacology | Research | Drug therapy | Dyspnea | Lung diseases | Fibrosis | Death | Skin | Respiration | Survival | Patients | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The rising incidence of idiopathic pulmonary fibrosis in the UK
by Navaratnam, V and Fleming, K M and West, J and Smith, C J P and Jenkins, R G and Fogarty, A and Hubbard, R B
Thorax, ISSN 0040-6376, 06/2011, Volume 66, Issue 6, pp. 462 - 467
BackgroundPrevious studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the UK and USA. Death registrations and primary... 
SURVIVAL | MORTALITY | DIAGNOSIS | PREVALENCE | ALVEOLITIS | RESPIRATORY SYSTEM | Idiopathic Pulmonary Fibrosis - epidemiology | Age Distribution | Idiopathic Pulmonary Fibrosis - mortality | Primary Health Care - statistics & numerical data | Epidemiologic Methods | Humans | Middle Aged | Aged, 80 and over | Sex Distribution | Aged | Mortality - trends | United Kingdom - epidemiology | Development and progression | Pulmonary fibrosis | Diagnosis | Patient outcomes | Codes | Mortality | Lung diseases | Data bases | Studies | Datasets | Medical prognosis | Population | Trends | Age | Cancer | Chronic illnesses
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension
by Mejía, Mayra and Carrillo, Guillermo and Rojas-Serrano, Jorge and Estrada, Andrea and Suárez, Teresa and Alonso, Delfino and Barrientos, Emilio and Gaxiola, Miguel and Navarro, Carmen and Selman, Moisés
Chest, ISSN 0012-3692, 07/2009, Volume 136, Issue 1, pp. 10 - 15
Background: It has been suggested that the presence of emphysema modifies the outcome of patients with idiopathic pulmonary fibrosis (IPF). In this article we... 
DESTRUCTION | ALVEOLITIS | RESPIRATORY SYSTEM | INFLAMMATION | COMPUTED-TOMOGRAPHY | DISEASE | Hypertension, Pulmonary - mortality | Pulmonary Emphysema - physiopathology | Prevalence | Pulmonary Ventilation | Humans | Middle Aged | Risk Factors | Hypertension, Pulmonary - physiopathology | Male | Survival Rate | Pulmonary Artery | Case-Control Studies | Idiopathic Pulmonary Fibrosis - mortality | Female | Aged | Idiopathic Pulmonary Fibrosis - complications | Idiopathic Pulmonary Fibrosis - physiopathology | Pulmonary Emphysema - epidemiology | Pulmonary Emphysema - mortality | Cohort Studies | Hypertension, Pulmonary - complications | Smoking | Complications and side effects | Pulmonary fibrosis | Prognosis | Emphysema, Pulmonary | Development and progression | Comparative analysis | Pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A multidimensional index and staging system for idiopathic pulmonary fibrosis
by Ley, Brett and Ryerson, Christopher J and Vittinghoff, Eric and Ryu, Jay H and Tomassetti, Sara and Lee, Joyce S and Poletti, Venerino and Buccioli, Matteo and Elicker, Brett M and Jones, Kirk D and King Jr, Talmadge E and Collard, Harold R
Annals of Internal Medicine, ISSN 0003-4819, 2012, Volume 156, Issue 10, pp. 684 - 695
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | STANDARDIZATION | PROGNOSTIC MODELS | RISK | CLASSIFICATION | CLINICAL-COURSE | PREDICTION | Prognosis | Age Factors | Risk Assessment | Humans | Middle Aged | Male | Lung - physiopathology | Models, Statistical | Idiopathic Pulmonary Fibrosis - surgery | Vital Capacity | Lung Transplantation | Pulmonary Diffusing Capacity | Idiopathic Pulmonary Fibrosis - diagnosis | Idiopathic Pulmonary Fibrosis - mortality | Female | Idiopathic Pulmonary Fibrosis - physiopathology | Retrospective Studies | Pulmonary fibrosis | Research | Physiology | Gender | Lung diseases | Mortality | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Clinical course and prediction of survival in idiopathic pulmonary fibrosis
by Ley, Brett and Collard, Harold R and King Jr, Talmadge E
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 02/2011, Volume 183, Issue 4, pp. 431 - 440
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF... 
Clinical course | Prognosis | Survival | Idiopathic pulmonary fibrosis | Predictors | predictors | clinical course | RESOLUTION COMPUTED-TOMOGRAPHY | WALK TEST | SURFACTANT PROTEIN-A | survival | idiopathic pulmonary fibrosis | prognosis | PROGNOSTIC VALUE | USUAL INTERSTITIAL PNEUMONIA | GASTROESOPHAGEAL-REFLUX | RESPIRATORY SYSTEM | ARTERIAL-HYPERTENSION | PLACEBO-CONTROLLED TRIAL | HISTOLOGIC PATTERN | ACUTE EXACERBATION | CRITICAL CARE MEDICINE | Idiopathic Pulmonary Fibrosis - mortality | Humans | Risk Factors | Cause of Death | Disease Progression | Survival Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
by Du Bois, Roland M and Weycker, Derek and Albera, Carlo and Bradford, Williamson Z and Costabel, Ulrich and Kartashov, Alex and Lancaster, Lisa and Noble, Paul W and Raghu, Ganesh and Sahn, Steven A and Szwarcberg, Javier and Thomeer, Michiel and Valeyre, Dominique and King Jr, Talmadge E
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 08/2011, Volume 184, Issue 4, pp. 459 - 466
Rationale: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have been described; however, there is a need for a practical and... 
Vital capacity | Interstitial lung disease | Mortality | Risk factors | SURVIVAL | risk factors | DISTANCE | SCORE | INTERSTITIAL PNEUMONIA | PROGNOSTIC VALUE | COMPUTED-TOMOGRAPHY | ATRIAL-FIBRILLATION | LUNG TRANSPLANTATION | vital capacity | COMMUNITY | interstitial lung disease | RESPIRATORY SYSTEM | mortality | CARDIOVASCULAR-DISEASE | CRITICAL CARE MEDICINE | Multivariate Analysis | Prognosis | Risk Assessment | Carbon Monoxide | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Clinical Trials as Topic | Vital Capacity | Pulmonary Diffusing Capacity | Idiopathic Pulmonary Fibrosis - mortality | Time Factors | Quality of Life | Female | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Health Status
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text All-cause mortality rate in patients with idiopathic pulmonary fibrosis: Implications for the design and execution of clinical trials
by King Jr, Talmadge E and Albera, Carlo and Bradford, Williamson Z and Costabel, Ulrich and Du Bois, Roland M and Leff, Jonathan A and Nathan, Steven D and Sahn, Steven A and Valeyre, Dominique and Noble, Paul W
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 04/2014, Volume 189, Issue 7, pp. 825 - 831
Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating novel therapies for patients with idiopathic pulmonary fibrosis (IPF).... 
Endpoints | Clinical trial | Hospitalization | Idiopathic pulmonary fibrosis | Mortality | clinical trial | SURVIVAL | endpoints | METAANALYSIS | hospitalization | RESPIRATORY SYSTEM | mortality | idiopathic pulmonary fibrosis | FORCED VITAL CAPACITY | CRITICAL CARE MEDICINE | Recombinant Proteins - therapeutic use | Follow-Up Studies | Interferon-gamma - therapeutic use | Randomized Controlled Trials as Topic - methods | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Models, Statistical | Cause of Death | Clinical Trials, Phase III as Topic - methods | Feasibility Studies | Sample Size | Idiopathic Pulmonary Fibrosis - mortality | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Pyridones - therapeutic use | Research Design | Idiopathic Pulmonary Fibrosis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
by Noth, Imre, Prof and Zhang, Yingze, PhD and Ma, Shwu-Fan, PhD and Flores, Carlos, PhD and Barber, Mathew, PhD and Huang, Yong, MS and Broderick, Steven M, BS and Wade, Michael S, MS and Hysi, Pirro, PhD and Scuirba, Joseph, BS and Richards, Thomas J, PhD and Juan-Guardela, Brenda M, MD and Vij, Rekha, MD and Han, MeiLan K, MD and Martinez, Fernando J, Prof and Kossen, Karl, PhD and Seiwert, Scott D, PhD and Christie, Jason D, MD and Nicolae, Dan, Prof and Kaminski, Naftali, Prof and Garcia, Joe GN, Prof
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 4, pp. 309 - 317
Summary Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease that probably involves several genetic loci. Several rare genetic variants and... 
Pulmonary/Respiratory | TRIAL | POLYMORPHISMS | INSTABILITY | RESPIRATORY SYSTEM | TOLL-INTERACTING PROTEIN | PROMOTER | MUC5B | CRITICAL CARE MEDICINE | United States - epidemiology | Genetic Predisposition to Disease | Idiopathic Pulmonary Fibrosis - genetics | Survival Rate - trends | Humans | Middle Aged | Genotype | Male | Linkage Disequilibrium | DNA - genetics | Genetic Variation | Phenotype | Idiopathic Pulmonary Fibrosis - mortality | Adult | Female | Aged | Retrospective Studies | Genome-Wide Association Study - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
by Martinez, Fernando J and De Andrade, Joao A and Anstrom, Kevin J and King Jr, Talmadge E and Raghu, Ganesh and The Idiopathic Pulmonary Fibrosis Clinical Research Network and Idiopathic Pulm Fibrosis Clinical and Idiopathic Pulmonary Fibrosis Clinical Research Network
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2093 - 2101
Acetylcysteine, which has been advocated as a treatment for patients with idiopathic pulmonary fibrosis, showed no benefit over placebo with respect to loss of... 
SAMPLE-SIZE | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | Azathioprine - therapeutic use | Prednisone - adverse effects | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Disease Progression | Acetylcysteine - adverse effects | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Treatment Failure | Female | Aged | Free Radical Scavengers - therapeutic use | Idiopathic Pulmonary Fibrosis - physiopathology | Acetylcysteine - therapeutic use | Drug Therapy, Combination | Azathioprine - adverse effects | Free Radical Scavengers - adverse effects | Idiopathic Pulmonary Fibrosis - drug therapy | Prednisone - therapeutic use | Clinical trials | Acetylcysteine | Pulmonary fibrosis | Research | Drug therapy | Analysis | Statistical analysis | Preservation | Lung diseases | Fibrosis | Prednisone | Azathioprine | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
by Karimi-Shah, Banu A and Chowdhury, Badrul A
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 13, pp. 1189 - 1191
In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change... 
MEDICINE, GENERAL & INTERNAL | United States | Humans | Enzyme Inhibitors - pharmacology | Drug Approval | Enzyme Inhibitors - therapeutic use | Cause of Death | Advisory Committees | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Vital Capacity - drug effects | Idiopathic Pulmonary Fibrosis - mortality | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Indoles - pharmacology | Indoles - therapeutic use | Idiopathic Pulmonary Fibrosis - physiopathology | Pyridones - therapeutic use | Idiopathic Pulmonary Fibrosis - drug therapy | Pyridones - pharmacology | United States Food and Drug Administration | Studies | Pulmonary fibrosis | Mortality | Lung diseases | Fibrosis | FDA approval | Drug therapy | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights